|
|
|
 |
Search published articles |
 |
|
Showing 4 results for Brain Metastasis
Dr. G. Yavas, C. Yavas, O.v. Gul, H. Acar, O. Ata,
Volume 12, Issue 4 (10-2014)
Abstract
Background: Palliative whole brain radiotherapy (WBRT) has been the standard treatment for brain metastases. Ionizing radiation is known to be one of the most potent cataractogenic agents. We aimed to evaluate two different radiotherapy techniques with respect to the doses received by the organs at risk (OAR) in patients with brain metastasis who undergone WBRT. Materials and Methods: Ten consecutive patients with brain metastasis were included. For each patient, two different treatment plans were created for whole brain. Helmet-field (HF) (anterior border was 2 cm posterior to lens, inferior border was the bottom of C2 vertebra) and classical technique with collimation (CT) (anterior border was defined as skin fall off, inferior border was the bottom of cranial base) were generated for all patients. Two techniques were compared with respect to the doses received by the OAR including bilateral lenses, optic nerves and eye-balls, the dose homogeneity index (DHI), and the monitor unit counts (MU) required for the treatment. Student-t test was used for statistical analysis. Results: There was no difference between two techniques in terms of both DHI (p: 0.182) and MU counts (p: 0.167). The maximum and mean doses received by the right lens, left lens and right eye-ball were significantly reduced with CT (p values for maximum doses 0.007, 0.012 and 0.010 for median doses 0.027, 0.046 and 0.002 respectively). Conclusion: CT was found to be more advantageous, with respect to the lens doses in addition the dose received by the right eye-ball during WBRT.
Dr. A. Mayadagli, H.s Kiziltan, I. Kingir Celtik, K. Berk, E. Tekce, A.h. Eris , H. Seyithanoglu,
Volume 16, Issue 2 (4-2018)
Abstract
Background: This study was performed to assess patient survival and treatment toxicity after helical tomotherapy (HT) with simultaneous integrated boost (SIB) radiotherapy (RT) for cancer patients with one to eight brain metastases (BM) who have been treated with or without surgery. Materials and Methods: A total of 48 brain metastasis (BM) patients were included in this retrospective study between April 2015 and December 2016,. The patients were treated with image-guided intensity modulated radiation therapy (IMRT) on the helical tomotherapy (HT) machine. Whole brain HT as 25 Gy and SIB to metastasis sites as 35 Gy was delivered in 10 fractions. The patient were aged between 50 to 80 years old, volume of the BM was between 6 to 75 cc and the number of brain metastasis was between 1 to 8, Karnofsky Performance Score (KPS) ranged between 50-90 and RPA I-III. Surgery was performed to two patients before RT. The maximum patient follow-up time was 20 months. Results: The primary neurotoxicity observed in patients was grade I- II brain edema related headache and lethargy. In patients who had survived 3- 12 months, KPS improved median score of 20 points and RPA was grade I after six months. Twelve patients had passed away at the end of a 20- month follow-up. Conclusion: HT utilizing SIB treatment for 1- 8 BM was achieved successfully with no significant toxicity. An improvement of performance status indicators of patients following RT was observed.
M.d., H.s. Kızıltan, G. Coban, P. Altınok, E. Tekce, A. Mayadagli,
Volume 21, Issue 1 (1-2023)
Abstract
Background: In this study, prognostic features of radiation were investigated in cancer patients with 1-10 brain metastases (BM) who have not under surgery and survived longer than 6 months. Materials and Methods: This retrospective study included 136 patients have lung, breast, colon cancer and malign melanoma (MM) with 1-10 BM. All patients and data of BM patients who lived longer than 6 months radiotherapy (RT) related factors affecting their survival rates were examined. Patients were given only WBRT (Whole brain Radiotherapy) in 8-20 fractions with a 160-300 cGy / day fraction, or WBRT with local boost RT with an additional daily 300-350 cGy fraction. Results: When the results were evaluated analysis showed that the having CT, breast cancer, a KPS of 60% or more, daily fraction dose of RT affected survival significantly in all patients. Then subgroub analysis were obtained according to survival rates, number of metastases more than 5 affects life negatively (r=-0.435 and p=0.03) for survival longer than 6 months (SL6m) and survival shorter or equal than 6 months SS6m. The WBRT doses of 3000 cGy with 300 cGy daily fraction size negatively affected life compared to 2500 cGy with 250 cGy (r=-0.280 and p=0.01). Conclusion: It was determined that KPS > 60 and limiting WBRT doses up to 250 / 2500 cGy daily and total in patients with BM between 1-10 was the important best prognostic factor due to RT for SL6m, which increased patient performance and survival rates.
Mm. S. Cao, Z. Shu ,
Volume 22, Issue 2 (4-2024)
Abstract
Background: The goal of this study was to create a prediction model for brain metastasis (BrMs) in patients with lung cancer using unenhanced spectral computed tomography (CT) and radiomics. Materials and Methods: This study comprised 162 patients with lung cancer who underwent spectral CT from 2019–2021. Patients were split into training and test sets and into BrMs and BrMs-free groups. Spectral and radiomics parameters were obtained from the spectral CT images before pathological confirmation. Prediction models in the training and test sets were created using logistic regression. The receiver operating characteristic curve was used to evaluate each quantitative parameter for predicting BrMs. The diagnostic effectiveness of several parameters was analyzed and compared using the area under the curve (AUC) calculation. The final model was obtained using the Delong test. Results: There were statistically significant differences in the iodine concentrations and the slope of the energy spectrum attenuation curve of the two groups <(p0.05). The AUC of the combined radiomics model was greater than that of the 70 keV and 120 keV sequence models. The joint parameters of radiomics and spectral CT constructed an integrated model. In the training set, test set, and overall set, the AUCs of the integrated model were 0.875, 0.879, and 0.724, respectively. In the training and overall sets, the prediction performance of the integrated model outperformed the spectral and radiomics models (p<0.05). Conclusions: This integrated model may predict the BrMs in lung cancer patients.
|
|
